limited metastatic disease
Recently Published Documents


TOTAL DOCUMENTS

14
(FIVE YEARS 3)

H-INDEX

5
(FIVE YEARS 1)

2021 ◽  
Vol 14 (6) ◽  
pp. e243495
Author(s):  
Abhijith Bhaskaran ◽  
Pooja Sethi ◽  
Pampa Ch Toi ◽  
Prasanth Penumadu

We present a case of a 34-year-old woman who presented with complaints of fever, cough and dyspnoea of 2 months’ duration. On evaluation, she was diagnosed with a rare entity primary pleural Ewing’s sarcoma with synchronous metastases to mediastinal, supraclavicular nodes and single vertebra. Due to the rarity of this entity and lack of treatment guidelines on extraosseous Ewing’s sarcoma, the patient was managed with a combination of multiagent chemotherapy, surgery and radiotherapy as per standard guidelines for skeletal Ewing’s sarcoma. We present this case to discuss differential diagnoses and management dilemmas encountered on the use of local modalities such as surgery and radiotherapy for control of primary and metastatic sites.


2019 ◽  
Vol 121 (11) ◽  
pp. 897-903 ◽  
Author(s):  
Thomas H. Beckham ◽  
Jonathan E. Leeman ◽  
Peng Xie ◽  
Xiaolin Li ◽  
Debra A. Goldman ◽  
...  

Abstract Background Our objective was to evaluate the outcomes of metastatic head and neck squamous cell carcinoma (HNSCC) by disease burden with an emphasis on metastasis-directed therapy (MDT) in patients with limited metastatic disease burden. Methods In total, 186 patients who developed metastatic disease after definitive therapy for HNSCC were included. Clinically and radiographically apparent metastases were enumerated. Kaplan–Meier methods were used to estimate survival. Cox regression was used to assess the association between clinical variables. Results Patients with a single metastasis had a 5-year overall survival (OS) of 35% (95% CI 16–54%) in contrast to patients with multiple metastases with a 5-year OS of 4% (95% CI 2–9%). Thirty patients (16.1%) underwent MDT. On multivariable analysis, oral cavity or sinonasal primary (HR 2.22 95% CI 1.16–4.25, p = 0.015; HR 4.88, 95% CI 1.10–21.70, p = 0.037, respectively) were associated with higher risk of death, whereas receipt of MDT (HR 0.36, 95% CI 0.17–0.74, p = 0.006) was associated with lower hazard of death. Median subsequent metastasis-free survival and 5-year survival after MDT (n = 30) were estimated at 26.4 months (95% CI: 9.8–54.0) and 31%, (95% CI: 15–48%). Conclusions HNSCC patients with limited metastatic disease may derive significant benefit from MDT. Prospective trials evaluating MDT in HNSCC are warranted.


2018 ◽  
Vol 127 ◽  
pp. S875-S876
Author(s):  
N.R. Khanna ◽  
A. Sasidharan ◽  
G. Chinnaswamy ◽  
T. Vora ◽  
J. Bajpai ◽  
...  

Author(s):  
Kaitlin M. Christopherson ◽  
Xiudong Lei ◽  
Carlos H. Barcenas ◽  
Thomas A. Buchholz ◽  
Karen Hoffman ◽  
...  

Author(s):  
Puneeth Iyengar ◽  
Steven Lau ◽  
Jessica S. Donington ◽  
Robert D. Suh

Distant metastasis is common in non–small cell lung cancer (NSCLC) and typically associated with poor prognosis. Aggressive local therapy including surgery and/or radiation for limited metastatic disease from colorectal cancer and sarcoma is associated with survival benefit and has become part of the standard of care. In this article, we review the literature and ongoing studies concerning surgery, radiation, and radiofrequency ablation for oligometastatic NSCLC.


2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
M. Berlière ◽  
F. P. Duhoux ◽  
L. Taburiaux ◽  
V. Lacroix ◽  
C. Galant ◽  
...  

The aims of this study were first to clearly define two different entities: locoregional recurrences and limited metastatic disease and secondly to evaluate the place of extensive surgery in these two types of recurrence.Material and Methods. Twenty-four patients were followed from June 2004 until May 2014. All patients underwent surgery but for 1 patient this surgery was stopped because the tumour was unresectable.Results. The median interval between surgery for the primary tumour and the locoregional recurrence or metastatic evolution was 129 months. Eight patients had pure nodal recurrences, 4 had nodal and muscular recurrences, 5 had muscular + skin recurrences, and 8 had metastatic evolution. Currently, all patients are still alive but 2 have liver metastases. Disease free survival was measured at 2 years and extrapolated at 5 years and was 92% at these two time points. No difference was observed for young or older women; limited metastatic evolution and locoregional recurrence exhibited the same disease free survival.Conclusion. Extensive surgery has a place in locoregional and limited metastatic breast cancer recurrences but this option must absolutely be integrated in the multidisciplinary strategy of therapeutic options and needs to be planned with a curative intent.


2014 ◽  
Vol 32 (26) ◽  
pp. 2902-2912 ◽  
Author(s):  
Joseph K. Salama ◽  
Michael T. Milano

Advances in radiotherapy planning and delivery have been used to treat patients with limited metastatic disease. With these techniques, high rates of treated metastasis control and low toxicity have been reported. Some patients have long disease-free intervals after radiotherapy similar to those seen after surgical resection. Ongoing studies will determine the benefit of these irradiation techniques to treat limited metastases, identify appropriate candidates, and assist in integrating these treatments into management strategies for specific diseases.


2013 ◽  
Vol 3 (4) ◽  
pp. 316-322 ◽  
Author(s):  
Kimberly S. Corbin ◽  
Mark C. Ranck ◽  
Michael D. Hasselle ◽  
Daniel W. Golden ◽  
Julien Partouche ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document